Transcripta Bio
Transcripta Bio
Transcripta Bio
AI-powered drug discovery company focused on neurological and neuromuscular diseases, leveraging transcriptomics to accelerate therapeutic development.
About
“Transcripta Bio Wins the Genomics Category 🧬💻. Transcripta Bio took home the trophy for Genomics, and for good reason. They are bridging the gap between massive transcriptomic data and actual drug candidates.”
View on RedditSome comments are pulled from public discussions around the web (look for the source icon). Quotes are excerpts; click through to read the full thread.
What does Transcripta Bio do?
Transcripta Bio is an AI-powered drug discovery company dedicated to developing novel therapeutics for neurological and neuromuscular diseases. The company's closed-loop discovery engine uses transcriptomic signature matching to identify drug candidates whose molecular signatures are the inverse of patient-derived disease signatures, enabling a faster, more capital-efficient path to the clinic. They also leverage their proprietary AI model, Conductor AI, to predict new drugs that move gene expre…
How much funding has Transcripta Bio raised?
Transcripta Bio has raised a total of $24M in funding. The most recent round on record is Series A.
Where is Transcripta Bio headquartered?
Transcripta Bio is headquartered in Palo Alto, United States.
When was Transcripta Bio founded?
Transcripta Bio was founded in 2023.
What industry does Transcripta Bio operate in?
Transcripta Bio operates in Biotechnology, Artificial Intelligence, Drug Discovery, Neurology, Neuromuscular Diseases, Biotech.
What is Transcripta Bio's revenue?
StartupHub estimates Transcripta Bio's annual revenue at $2.9M (range $787K to $8.8M, 36% confidence), based on comparable companies in the sector.
What is Transcripta Bio's valuation?
StartupHub estimates Transcripta Bio's effective valuation at $96.0M (range $60.0M to $144.0M, 25% confidence), based on comparable companies in the sector.